Aptose Biosciences Inc. Files Definitive Proxy Statement

TL;DR

APTO proxy filing out for Jan 27 meeting - vote on directors & auditors.

AI Summary

Aptose Biosciences Inc. filed a Definitive Proxy Statement (DEF 14A) on December 30, 2024, for its annual meeting on January 27, 2025. The filing details the company's governance, executive compensation, and proposals to be voted on by shareholders, including the election of directors and ratification of its independent registered public accounting firm.

Why It Matters

This filing provides shareholders with crucial information regarding company leadership and voting matters, enabling informed participation in corporate governance decisions.

Risk Assessment

Risk Level: low — This is a routine proxy filing providing information to shareholders and does not inherently present new financial risks.

Key Players & Entities

• Aptose Biosciences Inc. (company) — Registrant
• 0000882361 (company) — Central Index Key
• 20250127 (date) — Annual Meeting Date
• 20241230 (date) — Filing Date

FAQ

Filing Documents

• d866874ddef14a.htm (DEF 14A) — 184KB
• g866874g00m18.jpg (GRAPHIC) — 192KB
• g866874g00m19.jpg (GRAPHIC) — 126KB
• g866874g0423115746058.jpg (GRAPHIC) — 4KB
• 0001193125-24-286050.txt ( ) — 630KB

From the Filing

DEF 14A 1 d866874ddef14a.htm DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 Aptose Biosciences Inc. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) Table of Contents N OTICE AND P ROXY S TATEMENT F OR THE S PECIAL M EETING OF S HAREHOLDERS TO BE HELD ON J ANUARY 27, 2025 December 24, 2024 Table of Contents Aptose Biosciences Inc. Notice of Special Meeting of Shareholders NOTICE IS HEREBY GIVEN that the special meeting (the Meeting ) of shareholders of Aptose Biosciences Inc. (the Corporation) will be held on January 27, 2025 at 7:00 a.m. (Pacific Standard time). The Meeting will be conducted in a virtual format only. There will be no physical location for shareholders and duly appointed proxyholders to attend. Shareholders and duly appointed proxyholders are invited to attend the Meeting by live webcast accessible directly online at https://meetings.lumiconnect.com/400-993-634-523, where they will be able to listen, vote, and submit questions during the Meeting. What the Meeting is About The following items of business will be covered at the Meeting: 1. Proposal No. 1 passing a special resolution, the full text of which is set forth in the Proxy Board considers it to be in the best interests of the Corporation to implement such Reverse Stock Split, all as more particularly described in the Proxy Statement; 2. Proposal No. 2 passing a resolution, the full text of which is set forth in the Proxy Statement, approving one or more adjournments of the Meeting, if necessary or appropriate, if a quorum is present, to permit further solicitation of proxies if there are not sufficient votes at the time of the Meeting to approve Proposal No. 1; and 3. transacting such other business as may be properly brought before the Meeting. The shareholders may also consider other business that properly comes before the Meeting or any adjournment of the Meeting. The Proxy Statement provides additional information relating to the matters to be dealt with at the Meeting and forms part of this notice. You have the right to vote. You are entitled to receive notice of and vote at the Meeting, or any adjournment, if you are a holder of common shares in the capital of the Corporation (Shares) at the close of business on December 24, 2024. You have the right to vote your shares on items 1 through 2 listed above and any other items that may properly come before the Meeting or any adjournment. The Notice of Meeting, Proxy Statement and the form of proxy will be mailed to you on or around January 6, 2025. Detailed instructions regarding shareholders voting process are also available on our website at https://www.aptose.com/investors/news-events/ir-calendar. Your vote is important. If you are not able to attend the Meeting, please exercise your right to vote by signing and returning the enclosed form of proxy to Computershare Investor Services Inc., 100 University Avenue, 8 th Floor, Toronto, Canada M5J 2Y1, so as to arrive not later than 10:00 a.m. (Toronto time) on January 23, 2024 or, if the Meeting is adjourned, 48 hours (excluding Saturdays, Sundays and holidays) before any adjournment of the Meeting. BY ORDER OF THE BOARD OF DIRECTORS William G. Rice, Ph.D. Chairman, President and Chief Executive Officer December 24, 2024 Table of Contents IMPORTANT NOTICE REGARDING THE INTERNET AVAILABILITY OF PROXY MATERIALS FOR THE SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 27, 2025. Our Notice of Special Meeting of Shareholders and Proxy Statement are available on the Corporations website at https://www.aptose.com/investors/news-events/ir-calendar . Copies are also available upon written request to the Senior Vice President, Chief Financial Officer, Chief Business Officer and Corporate Secretary (i) at our registered office located at 66 Wellington St W Suite 5300, Toronto, Ontario, Canada, M5K 1E6; or (ii) at our executive headquarters located at Suite 120, 12770 High Bluff Drive, San Diego, California, 92130. Table of Contents TABLE OF CONTENTS GENERAL INFORMATION ABOUT THE PROXY STATEMENT 1 QUESTIONS ABOUT THE SPECIAL MEETING AND V

View Full Filing

View this DEF 14A filing on SEC EDGAR